Kengrexal (cangrelor)
- Region
- 🇪🇺 EU
- Active substance
- cangrelor
- Company
- Chiesi Farmaceutici S.p.A.
- Status
- Authorised
- Therapeutic area
- Acute Coronary Syndrome; Vascular Surgical Procedures
- CHMP opinion
- Thu 22 Jan 2015
- EU approval
- Mon 23 Mar 2015
- Designations
- Additional monitoring
- Application
- EMEA/H/C/003773
- ATC
- B01
- Official record
- www.ema.europa.eu
Indication
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
Regulatory milestones
No milestones recorded in the last year.
Follow Kengrexal
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.